Bank of America’s Soleno Therapeutics SLNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-439,902
Closed -$14.7M 5817
2026
Q1
$14.7M Buy
439,902
+231,307
+111% +$9.07M ﹤0.01% 2642
2025
Q4
$9.66M Buy
208,595
+46,497
+29% +$2.55M ﹤0.01% 2885
2025
Q3
$11M Sell
162,098
-76,545
-32% -$5.67M ﹤0.01% 3214
2025
Q2
$20M Sell
238,643
-191,416
-45% -$14.3M ﹤0.01% 2555
2025
Q1
$30.7M Buy
430,059
+380,110
+761% +$18.5M ﹤0.01% 2022
2024
Q4
$2.25M Buy
49,949
+110
+0.2% +$5.7K ﹤0.01% 4350
2024
Q3
$2.52M Sell
49,839
-20,816
-29% -$997K ﹤0.01% 4387
2024
Q2
$2.88M Sell
70,655
-2,171
-3% -$92K ﹤0.01% 4121
2024
Q1
$3.12M Buy
72,826
+15,356
+27% +$695K ﹤0.01% 4064
2023
Q4
$2.31M Buy
57,470
+53,572
+1,374% +$1.52M ﹤0.01% 4260
2023
Q3
$115K Buy
3,898
+1,805
+86% +$10.9K ﹤0.01% 6192
2023
Q2
$8.98K Hold
2,093
﹤0.01% 6893
2023
Q1
$4.48K Buy
2,093
+2,092
+209,200% +$4.7K ﹤0.01% 7091
2022
Q4
$2 Buy
+1
New +$1 ﹤0.01% 8162
2022
Q1
Sell
-7
Closed 8705
2021
Q4
$0 Buy
+7
New +$73 ﹤0.01% 8596
2021
Q3
Sell
-466
Closed -$8K 8361
2021
Q2
$8K Sell
466
-2,322
-83% -$39.2K ﹤0.01% 7353
2021
Q1
$53K Buy
2,788
+1,932
+226% +$62.3K ﹤0.01% 6617
2020
Q4
$24K Buy
856
+561
+190% +$16.2K ﹤0.01% 6549
2020
Q3
$11K Sell
295
-229
-44% -$6.69K ﹤0.01% 6434
2020
Q2
$17K Sell
524
-21
-4% -$910 ﹤0.01% 6308
2020
Q1
$19K Buy
545
+543
+27,150% +$23.1K ﹤0.01% 6196
2019
Q4
$0 Sell
2
-85
-98% -$2.17K ﹤0.01% 7365
2019
Q3
$2K Buy
+87
New +$2.77K ﹤0.01% 7011
2019
Q2
Hold
0
7390
2019
Q1
Hold
0
7388
2018
Q4
Sell
-10
Closed -$292 7352
2018
Q3
$0 Buy
+10
New +$363 ﹤0.01% 7450
2017
Q3
Sell
-91
Closed -$3K 7244
2017
Q2
$3K Buy
+91
New +$4.22K ﹤0.01% 6683
2017
Q1
Sell
-1
Closed 7202
2016
Q4
$0 Sell
1
-16
-94% -$1.11K ﹤0.01% 7284
2016
Q3
$1K Buy
+17
New +$1.29K ﹤0.01% 6963
2016
Q2
Hold
0
7346

Bank of America's SLNO Position: Q2 2026 in Review

Bank of America sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 439,902 shares — an estimated $14.7M sold.

Bank of America first reported a position in SLNO in Q3 2016 and held it in 27 quarters. The position peaked at $30.7M in Q1 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Bank of America reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bank of America sold 439,902 Soleno Therapeutics shares in Q2 2026, an estimated $14.7M.
  • Bank of America first reported a position in Soleno Therapeutics in Q3 2016 and held it in 27 quarters.
  • Bank of America's Soleno Therapeutics position peaked at $30.7M in Q1 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.